BUSINESS

Solasia Grabs China Approval for Antiemetic Patch Drug

July 25, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Solasia Pharma, a Tokyo-based oncology specialty firm, said on July 24 that its transdermal patch Sancuso (granisetron) was approved in China for the prevention of chemotherapy-induced nausea and vomiting (CINV). Solasia licensed the drug, a 5-HT3 receptor antagonist, from ProStrakan,…

To read the full story

Solasia to Grant MAAB Rights to Antiemetic Drug in China
January 26, 2026

BUSINESS

Sawai to End Teribone Generic Sales following Patent Settlement
February 26, 2026
Darzquro Seen as Emerging Standard in High-Risk SMM: Specialist
February 26, 2026
Jardiance Tops Five Promotion Channels in January: Intage
February 26, 2026
Towa Wins Pediatric Autism Use for Abilify Generic
February 26, 2026
Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…